Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Pain. 2022 Feb 2;163(8):e899–e916. doi: 10.1097/j.pain.0000000000002604

Figure 1. Steady-state physiological levels of E2, but not acute E2 treatment, attenuates 5HT-evoked orofacial pain behaviors.

Figure 1.

5HT-evoked orofacial pain behaviors were not significantly different in OVX females that received 2 μg E2 (light gray bars), 20 μg E2 (dark gray bars), or 200 μg E2 (closed bars) one hour prior to receiving 5HT injection as compared to vehicle control (open bars) (A). 5HT-evoked pain behaviors were significantly reduced in OVX females that were administered with steady-state physiological levels of 5% E2 (light gray bars) and 20% E2 capsules (dark grey bars) compared to vehicle control (open bars) at 0-6 min (B). Attenuation was also reported in the 5% E2 group at 13-18 min time bout. Attenuation was not observed in animals that received 40% E2 capsules (closed bars). *Denotes significant number of forelimb swipes compared to vehicle with significance in pairwise comparisons tested at p ≤ 0.05.